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Male circumcision protects against cancer of the penis, the invasive form of which is a devastating disease conﬁned almost
exclusively to uncircumcised men. Major etiological factors are phimosis, balanitis, and high-risk types of human papillomavirus
(HPV), which are more prevalent in the glans penis and coronal sulcus covered by the foreskin, as well as on the penile shaft,
of uncircumcised men. Circumcised men clear HPV infections more quickly. Phimosis (a constricted foreskin opening impeding
the passage of urine) is conﬁned to uncircumcised men, in whom balanitis (aﬀecting 10%) is more common than in circumcised
men. Each is strongly associated with risk of penile cancer. These ﬁndings have led to calls for promotion of male circumcision,
especially in infancy, to help reduce the global burden of penile cancer. Even more relevant globally is protection from cervical
cancer,which is10-times morecommon,being much higherin womenwith uncircumcised malepartners. Malecircumcisionalso
provides indirect protection against various other infections in women, along with direct protection for men from a number of
genital tract infections, including HIV. Given that adverse consequences of medical male circumcision, especially when performed
in infancy, are rare, this simple prophylactic procedure should be promoted.
1.Introduction
Penile cancer is a devastating disease, although uncommon
in developed countries. It accounts for less than 1% of all
malignancies in men in the USA and 0.1% of cancer deaths.
The 5-year survival rate is approximately 50% [1], having
decreased little over recent decades [2, 3]. The disease is
conﬁned almost exclusively to men who are uncircumcised,
the lifetime risk of penile cancer in an uncircumcised man
being 1 in 600 in the USA and 1 in 900 in Denmark [2].
These ﬁgures are not to be confused with the often quoted
annual incidence ﬁgure of the order of 1 in 100,000 [1, 4]. In
the USA the annual incidence of primary malignant penile
cancer decreased from 0.84 per 100,000 men in 1973 to 0.58
per100,000in2002[5].Squamouscellcarcinomaisthemost
common type of penile cancer. In the USA it represents 93%
of all penile malignancies [6]. From 1998 to 2003, 4,967
men were diagnosed with invasive squamous cell carcinoma,
representing less than 1% of all new cancers in men and
occurringat0.81casesper100,000USmenovertheﬁveyears
[7]. In 2010 there were 1,250 new cases of penile cancer and
310 deaths [8].
In the USA, Hispanic men have the highest incidence
(0.66per100,000),thenBlackmen(0.40per100,000),White
(0.39), American Indians (0.28), and Asian-Paciﬁc Islanders
(0.24) [6]. For ages >8 5y e a r si n c i d e n c ew a s4 . 7a n d3 . 6
per 100,000 in Hispanic and Black men, respectively [6]. A
decline in incidence by 1.9% per year in Blacks and 1.2%
in Whites between 1995 and 2003 has been attributed to
earlierdetectionandtreatment [6].Themajority (61%)were2 Advances in Urology
diagnoses at the localized stage. Diﬀerences were apparent
according togeographical region. Otherﬁgures, published in
2007, give annual incidence ﬁgures of 1.01 per 100,000 for
white Hispanics, 0.77 for Alaskan native/American Indians,
0.62per100,000for Blacksand 0.51fornon-Hispanic whites
[5]. These ﬁgures correlate inversely with incidence of male
circumcision in these groups.
2.LackofCircumcisionasaMajor Risk
FactorforPenileCancer
An extensive review in 2006 concluded that penile cancer is
an “emerging problem”, noting that “public health measures,
such as prophylactic use of circumcision, have proven
successful” [10]. Neonatal circumcision virtually abolishes
the risk [11].
The penile cancer incidence data for the USA have to be
viewed in the context of the high proportion of circumcised
men, especially in older age groups, and the age group
aﬀected, where mean age at presentation is 60 years [12].
Thus an incidence of approximately 1 in 100,000 males per
year of life translates to 75 in 100,000 during each man’s
lifetime (assuming an average life expectancy of 75years).
However, when one considers that penile cancer occurs
almost entirely in uncircumcised men, by assuming that
these represent 30% of males in the USA, the chance of an
uncircumcised man getting penile cancer would be 75 per
30,000, that is, 1 in 400, which accords with the lifetime risk
noted above [2].
In ﬁve major series in the USA, starting in 1932 [13], not
one man with invasive penile cancer had been circumcised
neonatally [3]. Another report noted 50,000 cases of penile
cancer in the USA from 1930 to 1990, resulting in 10,000
deaths [14]. Only 10 of the cases occurred in circumcised
men, but all of these men had been circumcised later in
life. Penile cancer is in fact so rare in a man circumcised in
infancy, that when it does occur it can be the subject of a
published case report [15]. The ﬁnite residual risk is greater
in those circumcised after the newborn period but is still less
than for men who are not circumcised [16]. In Saudi Arabia,
where circumcision is performed in older children, penile
cancer in circumcised men (average age 62) was associated
with ritual, nonclassical, so-called “vigorous”, circumcision
[17].
In circumcised men, the very low lifetime risk has been
estimated as 1 in 50,000 to 1 in 12,000,000 [18, 19]. For 213
cases in California only 2 of 89 men with invasive penile
cancer had been circumcised in infancy, so these authors
concluded that uncircumcised men had a 22-fold higher
risk [20, 21]. Of 118 patients with the localized, and thus
more easily curable, variety of penile cancer—carcinoma in
situ (which is not lethal)—only 16 had been circumcised
as newborns, that is, incidence was 7.3-fold higher in the
uncircumcised [3, 20, 21]. A study in Louisiana found that
only 2 of 45 penile cancer patients had been circumcised in
infancy [22].
InDenmark,wherecircumcisionprevalenceis2%,penile
cancer has nevertheless been decreasing steadily [23]i n
parallel with an increase in indoor bathrooms, consistent
with improvedhygieneasapossiblefactor. Urbanunmarried
Danish men were more likely to develop cancers. Since the
rate of penile cancer in Denmark is slightly lower than in the
USA other factors besides circumcision would appear to be
relevant, be they diet, lifestyle, climate or other. The statistics
for Denmark have been used by opponents of circumcision
to draw a very tenuous conclusion that lack of circumcision
is not associated with penile cancer. The Danes themselves
have concluded that although their uncircumcised men
might appear to be at slightly lower risk, this is only 1 in
900 as opposed to 1 in 600 in the USA [2]. A study in
Spain concluded that “circumcision should be performed in
childhood [as a] prophylactic [to penile cancer]” [24].
As a historical point of interest, Diego Rivera,the famous
Mexican muralist, who was renowned for having multiple
sexual partners in a country where most men are uncircum-
cised, developed penile cancer [25]. He refused penectomy,
instead travelling to the Soviet Union for radiation therapy,
and died a painful death from the disease and the side eﬀects
of his therapy.
InAustralia, casesaveraged66peryearoverthedecadeto
2003 [26]. Typical age distribution of cases was 4% for men
in their 30s, 14% in their 40s, 15% in their 50s, 22% in their
60s, 31% in their 70s, and 12% aged over 80 [27]. One in
4 died as a result, the death rate being higher in older men.
The annual incidence of penile cancer was 0.8 per 100,000
population [27], that is, similar to the US ﬁgures above, and
was also similar in each state of Australia. Life-time (age 0–
74)riskwasestimatedas1in1,574males[27].AsintheUSA,
over two-thirds of older men in Australia are circumcised,
so the decline in the proportion of uncircumcised males
in the Australian population, that occurred when infant
male circumcision dropped precipitously in the 1970s,
would, by itself, be expected to be accompanied by a rise in
the incidence of penile cancer.
In Israel, where almost all males are circumcised, the rate
of penile cancer is extremely low: 0.1 per 100,000, that is, is
1/10th that of Denmark [28, 29].
Low- and middle-income countries have a much higher
incidence of penile cancer: approximately 3–10 cases per
100,000 per year [2]. In countries where circumcision is not
practicedroutinely,suchasthoseinSouthAmericaand parts
of Africa, penile cancer can be ten times more common
than in high-income countries, representing 10–22% of all
male cancers [1, 30, 31]. In Uganda and some other African
countries it is the most common malignancy in males,
leading to calls for more male circumcision [32]. Enormous
diﬀerences are, moreover, seen amongst low- and middle-
income nations corresponding to diﬀerences in circumcision
prevalence in each country or ethnic subgroup. In Puerto
Rico [29], India, and Brazil [33, 34], where most men are
uncircumcised, penile cancer is quite common. Brazil has
one of the highest rates of penile cancer, 6–14 per 100,000
males per year, comprising 2–6% of all male neoplasias, with
7%ofcasesoccurringinmenagedunder35,and39%inmen
older than 66 [33]. Among cases, 87% are uncircumcised.
All tumors seen in men circumcised in childhood were of
low grade, whereas 12% of those circumcised in adulthoodAdvances in Urology 3
had high-grade tumors [33]. In at least two Brazilian States
(Maranhao and Pernambuco) penile cancer is reportedly
the 2nd highest cause of carcinoma death in men (after
lung cancer). At the main oncology hospital in Recife,
Pernambuco (Brazil’s4th largest city), on average one or two
men each week need to have a penile amputation due to
this cancer, with prognosis very poor. Many years ago the
directors of this hospital were interested in starting a male
circumcision promotion program (D.T. Halperin, personal
communication).
A statement made in 1973 that “despite overwhelming
evidencefromurologicalsurgeonsthatneoplasmofthepenis
is a lethal disease that can be prevented by removal of the
foreskin, some physicians continue to argue against routine
newborn circumcision in a highly emotional fashion” [35]
is just as true today. In the interests of public health, such
denial of evidence needs to be successfully confronted and
countered.
3.The RoleofHumanPapillomavirus(HPV)
InfectioninEtiologyof PenileCancer
3.1. Overview. Cancer of the penis can present as carcinoma
in situ or invasive penile cancer. In the USA the proportion
of each of these is similar, 45% and 55%, respectively.
Invasive penile cancer is lethal, whereas carcinoma in situ
is comparatively benign. The former is not necessarily a
continuum of the latter [36].
HPV is present in most basaloid and warty carcinomas
which comprise 50% of cases [30]. Similarly, in women, half
of all vulvar carcinomas are HPV positive. In contrast, virtu-
allyallcervicalcancersarepositiveforhigh-risk HPVs.High-
risk HPV is found more frequently in verrucous carcinomas
than giant condylomas (which are caused by low-risk HPV).
Although relatively harmless, such benign condylomas are
readily apparent and can bequiteconfronting in appearance.
Keratinizing and verrucous carcinomas are HPV positive in
one-third of cases [30]. A Spanish study found HPV in 78%
ofpenilecarcinoma specimens, with84%ofthesecontaining
the most common high-risk type, HPV16, and 11% having
the second most common high-risk type, HPV18 [37]. A
Danish study found 65% of squamous cell carcinomas had
HPV, with 92% of these being HPV16 [38]. In Thailand,
HPV was found in 82% of penile cancers, of which 55%
had HPV18, 43% had the low-risk type HPV6, and a large
proportion had both [39].
In a review of 31 studies, representing 1466 penile
carcinomas, overall prevalence was 46.9% [9]. Of those
positive for HPV, prevalence of the diﬀerent types was
HPV16 (60.2%), HPV18 (13.4%), HPV6/11 (8.1%), HPV31
(1.2%), HPV45 (1.2%), HPV33 (1.0%), HPV52 (0.6%),
and other types 2.5%. The most frequent HPV-related
histological types were basaloid and warty squamous cell
carcinomas. Figure 1 shows the prevalence of HPV in these
and other types of squamous cell carcinoma.
There is good reason to suspect that the high-risk HPV
types (16, 18, and numerous rarer types) found in a large
proportion of cases, are involved in the causation of many
penile cancers [40] ,s i n c et h e ya r et h es a m ev i r a lt y p e sa sa r e
responsible for virtually all cases ofcervical cancer in women
(see below).
High-riskHPVtypesproduceﬂatwartsthatarenormally
only visible by application of dilute acetic acid (e.g., vinegar)
to the penis. The majority of HPV infections are subclinical;
moreover, HPVinfection ismoreprevalentin uncircumcised
men having balanoposthitis [41]. High-risk HPV prevalence
data should not be confused with genital warts incidence
ﬁgures. Genital warts are large and readily visible, and are
caused by the relatively benign HPV types 6 and 11 [42].
3.2. Circumcision Protects against HPV Infection. There have
been numerous studies comparing HPV prevalence in
circumcised and uncircumcised men in diﬀerent countries,
racial groups, and ages [7, 41, 43–58]( Table 1).
AlargemultinationalstudypublishedintheNewEngland
Journal of Medicine in 2002 detected HPV in 19.6% of
847 uncircumcised men, compared to only 5.5% of 292
circumcised men (overall odds ratio (OR) after adjusting
for potential confounding factors = 0.37; 95% conﬁdence
intervals (CI) = 0.16–0.85; P<. 001) [45]( Table 1(a)). (All
odds ratios cited in this paper are signiﬁcant at the P = .05
level unless otherwise indicated.) In this study, samples were
collected from the urethra and glans penis/coronal sulcus.
A study at an STI clinic in Copenhagen, Denmark, found
that being uncircumcised was associated with a 5-fold higher
likelihood of being infected with HPV [54]( Table 1(b)).
Among STI clinic attendees in the USA, HPV was 1.5 times
higher in uncircumcised men [44]( Table 1(c)). In Mexico,
men attending vasectomy clinics had 5 times higher HPV if
they were uncircumcised [57]( Table 1(g)).AnotherMexican
study,involving healthymilitary men, founda10-foldhigher
OR for persistent HPV infection in uncircumcised men
[48]( Table 1(f)). In the HIM study, involving men in the
USA, Mexico, and Brazil, high-risk HPV types were lower in
circumcised men (OR 0.70) as were low-risk HPV types (OR
0.63) [46]( Table 1(k)).
3.3.Meta-Analyses. Ameta-analysis of8studiespublishedin
2007 found an association of circumcision with a statistically
signiﬁcant reduced risk of penile HPV and related lesions
(OR = 0.56; 95% CI = 0.39–0.82) [60]. The meta-analysis
waspromptedbythepublicationofa “biased,inaccurateand
misleading meta-analysis” by Van Howe [61]. Other meta-
analyses of circumcision and STIs by Van Howe [62, 63]
have similarly been shown by experts in the ﬁeld to be
fundamentally ﬂawed [64–66]a n do n e[ 63]w a se v e ns h o w n
to contain false source data [66], thus accounting for its
surprising conclusion.
A subsequent meta-analysis, published in 2009, exam-
ined high-risk HPV types in 14 studies (5 US, 2 Mexican,
2 Australian and one each from England, Denmark, South
Korea,Kenya,andthemultinationalstudyin2002referredto
above). It assessed data for 5,880 circumcised men and 4,257
uncircumcised men, ﬁnding circumcision to be protective,
the OR for HPV infection being 0.52 (95% CI = 0.33–
0.82) [67]( Figure 2). This meta-analysis found a marginally4 Advances in Urology
Table 1: Prevalence of HPV at diﬀerent anatomical sites for circumcised and uncircumcised men in various studies in diﬀerent countries.
(a) Castellsagu´ eet al. (2002) [45]: Spain, Columbia, Brazil, Thailand, Philippines; 26% were aged ≤37, 57% were 38–56, 25% were ≥57 years
Site HPV Circumcised Uncircumcised
(n = 370) (n = 1543) AOR (95% CI)
Glans, coronal sulcus
Any HPV 5.5% 19.6% 0.37 (0.16–0.85)
(b) Svare et al. (2002) [54]: Copenhagen, Sweden, STI clinic
Site HPV Circumcised Uncircumcised
(n = 22) (n = 112) AOR (95% CI)
Glans, coronal sulcus,
Shaft, scrotum
Any HPV 9% 21% 0.20 (0.06–0.60)
(c) Baldwin et al. (2004) [44]: Tucson, Arizona, STI clinic, 42% white (non-Hispanic), 39% Hispanic, 19% indigenous, Paciﬁc Islander or Asian, age 18–70,
90% heterosexual, 82% single, condom users had 79% lower high-risk HPV and 42% higher low-risk HPV
Site HPV Circumcised Uncircumcised
(n = 232) (n = 89) AOR (95% CI)
Glans, coronal sulcus,
urethral meatus
Any HPV 19.8% 41.1% 0.34 (0.20–0.57)
High-risk 7.8% 18.8% 0.44 (0.22–0.90)
Low-risk 12.1% 22.3% 0.44 (0.23–0.81)
(d) Weaver et al. (2004) [58]: Seattle, university students, aged 18–25, 81% white, 6% Asian, 3% African American, 2% Latino, 8% other, 97% β-globin
DNA-positive
Site HPV Circumcised Uncircumcised
(n = 233) (n = 84) OR (95% CI)
Glans Any HPV 17% 32% Not shown
All sites Any HPV 31% 29% 0.95 (0.50–1.79; NS)
(e) Shin et al. (2004) [52]: South Korea, university students, 46% had ≥4s e xp a r t n e r s
Site HPV Circumcised Uncircumcised
(n = 296) (n = 40) OR (95% CI)
Coronal sulcus, meatus,
shaft, scrotum
Any HPV 7.0% 8.9% 1.8 (0.4–8.2; NS)
(f) Lajous et al. (2005) [48]: Mexico City, soldiers, age 16–40 (av. 23), average 3 sex partners. condom use with prostitutesdid not aﬀect HPV prevalence
Site HPV Circumcised Uncircumcised
(n = 95) (n = 830) AOR (95% CI)
Coronal sulcus, meatus,
shaft, scrotum
Any HPV 29.5% 44.0% 0.48 (0.30–0.77)
(g) Vaccarella et al. (2006) [57]: Mexico, 27 public vasectomy clinics in 14 states, average age 34 years, HPV was 60% less for condom users with regular
partners and 90% less with sex workers, high-risk and low-risk HPV stated as similar within each of circumcised and uncircumcised
Site HPV Circumcised Uncircumcised
(n = 247) (n = 532) AOR (95% CI)
Glans/coronalsulcus,
M e a t u s ,s h a f t ,s c r o t u m
Any HPV 2.4% 11.7% 0.20 (0.10–0.40)
(h) Partridge et al. (2007) [51]: Seattle,university students,age 18–20, white 85%, Asian/Paciﬁc Islander 8.3%, other 7.1%, unmarried
Site HPV Circumcised Uncircumcised
(n = 184) (n = 56) HR (95% CI)Advances in Urology 5
(h) Continued.
Site HPV Circumcised Uncircumcised
Glans, shaft, scrotum 1.2/100PY 1.7/100PY 1.1 (0.6–2.0; NS)
(i) Hernandez et al. (2008) [59]: Hawaii, university population, most white, single, average age 29, 77% heterosexual, 53% had had ≥6 female sex partners,
50% used condoms, all HIV-negative
Site HPV Circumcised Uncircumcised
(n = 299) (n = 80) AOR (95% CI)
Glans/coronal sulcus
Any HPV 29% 46% 0.51 (0.27–0.97)
High-risk 16% 31% 0.40 (0.18–0.90)
Low-risk 22% 39% 0.51 (0.25–1.08)
Multiple 12% 39% 0.28 (0.12–0.67)
Shaft
Any HPV 50% 60% 0.63 (0.42–1.22)
High-risk 34% 38% 0.70 (0.32–1.52)
Low-risk 45% 56% 0.59 (0.30–1.16)
Multiple 30% 36% 0.57 (0.26–1.28)
Urine
Any HPV 8% 16% 0.31 (0.08–1.16)
High-risk 1% 3% 0.18 (0.004–7.69)
Low-risk 7% 16% 0.28 (0.07–1.10)
Multiple 1% 0% —
Semen
Any HPV 6% 5% 1.09 (0.17–7.14)
High-risk 2% 0% —
Low-risk 6% 5% 0.86 (0.13–5.88)
Multiple 1% 0% —
Scrotum
Any HPV 40% 40% 0.82 (0.43–25.0)
High-risk 20% 20% 0.69 (0.33–2.38)
Low-risk 33% 35% 0.69 (0.33–1.43)
Multiple 14% 19% 0.53 (0.21–1.33)
External penis
Any HPV 57% 67% 0.58 (0.30–1.14)
High-risk 25% 23% 0.82 (0.28–2.38)
Low-risk 30% 36% 0.61 (0.25–1.47)
Any 20% 23% 0.52 (0.17–1.56)
Any site
Any HPV 78% 83% 0.49 (0.19–1.28)
High-risk 55% 58% 0.38 (0.11–1.28)
Low-risk 61% 67% 0.42 (0.14–1.25)
Multiple 39% 41% 0.35 (0.09–1.43)
(j) Nielson et al. (2009) [49]: Tucson and Tampa, aged 18–40, circumcised participants: white 76%, Indigenous 6%, black 1%, Asian/Paciﬁc Islander 2%,
other 4%; >6 sex partners 65%, condom use ≤ half = 56%, sex with partner with abnormal pap smear 26% for circumcised,11% for uncircumcised
Site HPV Circumcised Uncircumcised
(n = 389) (n = 74) AOR (95% CI)
Glans/coronal sulcus
Any HPV 29.8% 35.2% 0.44 (0.23–0.82)
High-risk 13.9% 18.3% 0.47 (0.22–0.99)
Low-risk 15.8% 16.9% 0.62 (0.29–1.29)
Shaft
Any HPV 40.2% 40.9% 0.53 (0.28–0.99)
High-risk 21.2% 25.4% 0.50 (0.25–1.00)6 Advances in Urology
(j) Continued.
Site HPV Circumcised Uncircumcised
Low-risk 19.1% 15.9% 0.85 (0.40–1.80)
Scrotum
Any HPV 25.9% 24.3% 0.73 (0.37–1.44)
High-risk 12.9% 12.9% 0.68 (0.29–2.06)
Low-risk 12.9% 11.4% 0.86 (0.36–2.06)
Urethra
Any HPV 7.8% 14.9% 0.17 (0.05–0.56)
High-risk 3.9% 2.1% 1.24 (0.14–10.8)
Low-risk 3.9% 12.8% 0.04 (0.01–0.23)
Semen
Any HPV 4.2% 7.1% 0.48 (0.12–1.96)
High-risk 3.1% 3.6% 0.41 (0.10–2.78)
Low-risk 1.1% 3.6% 0.41 (0.03–5.07)
Any site
Any HPV 51.2% 51.4% 0.53 (0.28–0.99)
High-risk 28.8% 31.2% 0.56 (0.30–1.06)
Low-risk 22.4% 20.3% 0.84 (0.43–1.67)
(k) Giuliano et al. (2009) [46]: USA (34%), Mexico (32%), Brazil (35%); age 18–70 (av. 32), 66% had >1 sex partner in past 3 months, 9% had had sex with
male,condomuse:always20%,sometimes32%.The respectiveOR became0.70(0.52–0.94),0.70(0.50–0.97),and 0.63(0.42–0.93)aftermultivariateanalysis
Site HPV Circumcised Uncircumcised
(n = 590) (n = 398) OR (95% CI)
Coronal sulcus, shaft, under foreskin, scrotum (all β-globin DNA-positive)
Any HPV 54.8% 62.2% 0.97 (0.68–1.39)
High-risk 41.8% 49.2% 0.93 (0.63–1.33)
Low-risk 33.1% 40.4% 1.15 (0.74–1.79)
(l) Auvert et al. (2009) [43]: RCT, South Africa,Black, age 18–24, average 4 lifetime sex partners, consistent condom use 25%, 5% HIV-positive
Site HPV Circumcised Uncircumcised
(643) (621) PRR (95% CI)
Urethra
High-risk 14.0% 23.2% 0.60 (0.46–0.79)
Multiple high-risk 4.2% 9.9% 0.43 (0.28–0.66)
(m) Tobian et al. (2009) [55]: Rakai 1 RCT, Kenya; age 15–49 years; only β-globin positive samples
Site HPV Circumcised Uncircumcised
(n = 307) (n = 302) RR (95% CI)
Glans/coronal sulcus
All HPV 35.6% 51.2% 0.70 (0.53–0.91)
High-risk 18.0% 27.9% 0.65 (0.46–0.90)
Low-risk 26.2% 39.4% 0.66 (0.49–0.91)
Multiple 4.3% 12.2% 0.35 (0.17–0.71)
(n) Gray et al. (2010) [47]: Rakai, Uganda; RCT; age 15–24 (22%), 25–35 (51%), >35 (26%); condom use (35%), >1 sex partners 42%; HPV at enrolment
(39%); data for 24 months: after circumcision
Site HPV Circumcised Uncircumcised
(n = 441) (n = 399) IRR (95% CI)
Glans/coronal sulcus
Any high-risk HPV 19.7% 29.4% 0.67 (0.50–0.90)
Single new high-risk HPV 12.9% 15.6% 0.89 (0.60–1.30)
Multiple new high-risk HPV 6.7% 14.8% 0.45 (0.28–0.73)
HPV16 3.6/100PYs 4.8/100PYs 0.75 (0.38–1.51)
HPV18 1.6/100PYs 5.3/100PYs 0.30 (0.12–0.75)
HPV31 1.6/100PYs 2.2/100PYs 0.74 (0.27–2.05)Advances in Urology 7
(n) Continued.
Site HPV Circumcised Uncircumcised
HPV33 0.5/100PYs 3.1/100PYs 0.17 (0.04–0.76)
HPV35 1.9/100PYs 3.7/100PYs 0.50 (0.21–1.21)
(Condom use) 22/100PYs 32/100PYs 0.68 (0.43–1.09)
(o) Tobian et al. (2011) [56]: Rakai, rural Uganda, RCT, age 15–49, consistent condom use 16%, HPV test at 12 months after circumcision, only β-globin
DNA positive samplesincluded, high-risk HPV signiﬁcantlyhigher on coronal sulcusthan on shaft
Site HPV Circumcised Uncircumcised
(n = 231) (n = 228) APR (95% CI)
Coronal sulcus
Any high-risk HPV 21.5% 36.3% 0.57 (0.39–0.84)
Multiple high-risk 7.4% 10.5% 0.71 (0.33–1.52)
Shaft
Any high-risk HPV 15.5% 23.8% 0.66 (0.39–1.12)
Multiple high-risk HPV 1.7% 3.8% 0.45 (0.09–2.27)
OR: odds ratio; AOR: adjusted odds ratio; NS: not signiﬁcant; RR: risk ratio; PPR: prevalence risk ratio; HR: hazard ratio, 100PY: 100 person years.
Basaloid SCC
Warty SCC
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Figure 1: Prevalence of HPV in diﬀerent histologicaltypes of squamous cell carcinoma of the penis. Bars indicate 95% conﬁdence intervals.
Modiﬁed from Miralles-Guri et al. [9].
lower prevalence of low-risk HPV types in circumcised men,
although this was not statistically signiﬁcant (OR 0.89; 95%
CI 0.59–1.33). This is likely because low-risk HPV types are
associated with visible warts that tend to occur on the shaft
of the penis, a site of infection unlikely to be aﬀected by
circumcision [67].
3.4. Distribution of HPV on Penis. High-risk HPV types
exhibit a much higher prevalence with proximity to the tip
of the penis (Figure 3). In an early study, the distribution
of HPV was reported as 28% foreskin, 24% shaft, 17%
scrotum, 16% glans, and 6% urine [58]( Table 1(d)). In
another study, HPV prevalence ranged from 41% on the
shaft to 4.7% in semen [49]( Table 1(j)). The strength of
the association between circumcision and reduced HPV
decreased with distance from the prepuce/urethra, with
the adjusted OR being 0.17 for the urethra, 0.44 for the
glans/corona, and 0.53 for the shaft, with no signiﬁcant
diﬀerence found for the scrotum, perianal area, anal canal
and semen [49]( Table 1(j)). A study in Hawaii of men
who were primarily heterosexual found HPV infection of
the glans/coronal sulcus to be 46% in uncircumcised men
compared with 29% in circumcised men [59]( Table 1(i)).
This study also found that uncircumcised men had a
signiﬁcantly higher risk of oncogenic HPV types (adjusted
OR 2.51) and infection with multiple HPV types (adjusted
OR 3.56). In uncircumcised men, HPV prevalence on the
foreskin (44%) was comparable to that on the glans/coronal
sulcus. A study of 2,705 uncircumcised men aged 17–28 in
Kisumu, Kenya found high-risk HPV prevalence to be 31.2%
on the glans and 12.3% on the shaft (P<. 0001) [53]. In8 Advances in Urology
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Figure 2: Diﬀerence in prevalence of high-risk HPV types between
circumcised and uncircumcised men.
Figure 3: The circumcised and uncircumcised penis, depicting the
diﬀerences in prevalence of HPV between each.
Amsterdam, HPV16 was the most common type, with 29%
infected with more than one type. Not surprisingly, men
with HPV were also more likely to have other STIs. Only 1%
of men had visible genital warts. A randomized controlled
trial (RCT) has yielded similar ﬁndings, as will be presented
below.
3.5. Randomized Controlled Trials. The protection aﬀorded
by circumcision against HPV prevalence on the penis is
supported by RCTs in two localities. One of these, conducted
in Uganda and published in the New England Journal
of Medicine, found that 24months after circumcision the
prevalence of high-risk HPV in swabs from the coronal
sulcus of the penis was 18% compared to 28% in the
uncircumcised men in the control arm of the trial, giving
an adjusted prevalence ratio of 0.65, indicative of a 35%
protective eﬀect of circumcision [55]( Table 1(m)). When
conﬁning the analysis to samples positive for β-globin
(meaning cellular DNA was present), HPV was found in
14.9% of the circumcised group compared with 26.5% of
the uncircumcised group, pointing to a 44% protective
eﬀect [55]. Multiple high-risk HPV types were detected in
4.3% of circumcised men and 12.2% of uncircumcised men,
indicating a 65% protective eﬀect of circumcision against
these [55] .T h ep r e v a l e n c eo fn o n - h i g h - r i s kH P Vt y p e s
was 26% versus 39%, in circumcised and uncircumcised,
respectively, indicating a protective eﬀect of 35% [55]. These
researchers later reported data for the shaft in which they
only included swabs that were positive for high-risk HPV
by the Roche Linear array assay or for β-globin DNA.
At 12 months, high-risk HPV was present in 15.5% of
shaft samples from 121 circumcised men and 23.8% of 171
uncircumcised men (prevalence risk ratio (PRR) = 0.65),
indicating 35% protection [56]( Table 1(o)). Multiple HPV
types were found on the shaft of 1.7% of circumcised
and 3.8% of uncircumcised men (PRR = 0.45). For the
coronal sulcus these values were 21.5% and 36.3% (PRR =
0.59) for any high-risk HPV type in the circumcised and
uncircumcised arms of the trial, and 7.4% and 10.5% (PRR
= 0.71)for multiplehigh-risk HPV types. HPV was therefore
detected more frequently on the coronal sulcus than the
shaft.
In another report from the Rakai trials, among 230
circumcised men, 14% acquired new HPV infections over
24months, compared to 25% of 267 uncircumcised men,
giving an adjusted incidence rate ratio of 0.58, meaning
a 42% protective eﬀect [68]. The acquisition of multiple
high-risk HPV types was 6.7 cases per 100 person years
in the intervention arm and 14.8 cases per 100 person-
years in the control arm [47]( Table 1(n)). The protective
eﬀect was similar for all HPV types. In men who were
HIV-positive, the Rakai trial found that multiple new HPV
types, both low-risk and high-risk, were acquired in 9.9% of
intervention arm subjects and 24.7% of control arm subjects
(relative risk (RR) = 0.40; P = .01) [69]. The incidence of
multiple high-risk HPV infections was reduced signiﬁcantly
in HIV-negative (RR = 0.45) and HIV-positive (RR = 0.53)
men [70]. Statistical modeling which accounted for complex
correlation within individuals and between HPV genotypes
has shown that the current as-treated eﬃcacy of male
circumcision for prevention of high-risk HPV infections
is greater than the originally reported eﬃcacy which used
the individual participant as the unit of analysis [71].
The absence of statistical signiﬁcance of sex frequency and
condom use in the multivariate model implied that partner’s
HPVcarrierstatuswasthefundamentaldeterminantofHPV
incidence observed in the men studied.
In another RCT, in South Africa, high-risk HPV in
urethral swabs was 34% lower in the circumcised group
at 21months after surgery [43]( Table 1(l)). The authors
stated,moreover,thatowingtothefactthatsomemenwould
have already been infected with HPV before inclusion inAdvances in Urology 9
the trial, the actual eﬀect of circumcision on incident HPV
could have been greater than the reduction reported. Others
have pointed out that HPV detection may have been less
than optimal owing to sampling at the urethra rather than
the glans, coronal sulcus, or shaft, so underestimating the
eﬃcacy of circumcision in reducing HPV [72, 73]. Being
positive for HIV was associated with infection by multiple
HPV types (OR = 4.0) [74].
The South African RCT found that HIV infection was
higherinmenpositiveforhigh-riskHPV(adjustedincidence
rate ratio (IRR) = 3.8; P<. 001), an association that sug-
gested that high-risk HPV could facilitate HIV acquisition
[75]. However, confounding by sexual behavior and concur-
rent transmission of each virus is possible, meaning that the
validity of this assertion remains uncertain. Circumcision
reduced low-risk HPV infections in both HIV-negative and
HIV-positive men [75]. In the Kenyan RCT, after controlling
for baseline herpes simplex virus-2 serostatus, as well as
sexual and sociodemographic status, the hazard ratio for
HIV infection among men positive for HPV in glans/coronal
sulcus specimens was 1.8 compared with men negative for
HPV in such specimens (P = .03) [76].
3.6. Why HPV Is Higher in Uncircumcised Men. In uncir-
cumcised men, the moist subpreputial space likely provides
a more hospitable environment for infection by viruses than
the drier environment of the penis lacking a foreskin [77–
79]. In women the genital tract can provide a site that
acts as a reservoir for high-risk HPV infection at other
anatomical sites in the woman [80]. Thus circumcision
should reduce autoinfection of other sites in men too, one
being the shaft, so explaining the lower infection in the
shaft of circumcised men. High-risk HPV replicates in basal
epithelial cells of the epidermis [81]. The inner mucosa of
the foreskin is only lightly keratinized [78, 82, 83]. Earlier
discrepancies in the ﬁndings on keratinization most likely
resulted from diﬀerences in how foreskin tissue was handled
and processed subsequent to its excision [84]. The lower
keratinization of the foreskin may facilitate access of high-
risk HPV to underlying epithelial cells in uncircumcised
men. After circumcision, the keratinization of the surgical
scar and surrounding tissue would help reduce such epithe-
lial infection. These salient features of the uncircumcised
and circumcised penis may help explain why high-risk HPV
infection is lower in both the coronal sulcus and the shaft of
the circumcised penis.
3.7. Circumcised Men Clear HPV Faster. Although HPV
seroprevalence was found to be similar in circumcised and
uncircumcised men in a longitudinal study in New Zealand
[85], indicating similar exposure, the penile prevalence was
lower in circumcised men. The explanation is that circum-
cised men eliminate the infection faster, with serostatus
reﬂectingpreviousinfectioninsomecases.Insupportofthis,
a longitudinal study in Tucson, Arizona, of 285 men aged
18–44 found that circumcised men clear penile oncogenic,
but not nononcogenic, HPV infections 6 times faster than
do uncircumcised men [86]. In Hawaii, 357 men of average
age 29 years, 19% of whom were uncircumcised and 75% of
whom were heterosexual with an average of 6.5 prior female
sex partners, were tested for HPV types every 2months
f o r1 4 m o n t h s[ 87]. Although there was no diﬀerence in
acquisition of HPV, the clearance of HPV, including that
of oncogenic types, from the glans/coronal sulcus took
3months in the men who were circumcised, compared
with 5 months for those who were not (P = .04). There
was no diﬀerence for the shaft or scrotum. In the RCT in
Rakai, Uganda, clearance of pre-existing HPV was higher in
circumcised men at 216 cases per 100 person years in the
interventionarmcomparedto159casesper100person-years
in the control arm—adjusted RR = 1.39 [47].
The ability of circumcised men to clear high-risk HPV
faster would further explain their lower risk of penile cancer,
and of cervical cancer in their female partner(s). Moreover,
as mentioned above, in healthy Mexican military men, OR
for persistent HPV infectionw a s1 0 - t i m e sh i g h e ri nt h o s e
who were not circumcised [48]. Interestingly, men who had
had 16 or more lifetime sex partners were 4.9 times more
likely to clear oncogenic HPV infection than men with fewer
partners, possibly because of acquired immunity [86].
3.8. Vaccination of Males against High-Risk HPV Is Not
the Ideal Solution. Female-to-male transmission of HPV
involves cervix to penis transmission most frequently, with
the glans being most vulnerable [88]. The risk of trans-
mission from the cervix to the penis is 17% per month of
exposure,comparedwith5%fortransmission fromthepenis
to the cervix. After clearance of the virus in one member of
the dyad, reinfection in the couplecanoccur. In a study of14
high-risk HPV types, resistance to infection was lost at a rate
of 1–5% per year the older the subjects became [89].
High transmission potential with a low impact on herd
immunity means extensive vaccination would be required
to substantially reduce the incidence of cancer of the cervix
and penis caused by high-risk HPV types [89]. Further,
vaccination of males against HPV appears to represent an
expensive, ineﬃcientmeasureforpreventionofpenilecancer
[90], particularly when one considers that high-risk HPV is
presentinonlyhalfofpenilecancers.Ontheotherhand, lack
ofcircumcisionisariskfactor forphimosis and balanitis (see
below) which themselves are risk factors for penile cancer.
This would explain why invasive penile cancer is rare in
circumcised men, rather than being merely half as common
as one might predict based on just the single, but important,
risk factor of high-risk HPV [91]. HPV vaccination of males
should nevertheless help reduce cervical, anal and perhaps
oropharyngeal cancers.
The International Consultation on Penile Cancer deter-
mined in November 2008 that the factors associated with
invasive penile cancers were high-risk HPV infection (level
of evidence 3a–4), phimosis (level of evidence 3a), and
balanitis (3a) [92] .I nt h es a m ei s s u eo fUrology, the 2009
International Consultation on Urologic Disease Consensus
Publishing Group pointed to the well-established role of
HPV subtypes in the etiology of cancer of the penis and
suggested circumcision and early treatment of phimosis,10 Advances in Urology
together with signiﬁcant changes in global health policy, in
addressing this problem [93].
3.9. Penile Intraepithelial Neoplasia (PIN) and Cervical
Intraepithelial Neoplasia (CIN). Interestingly, 93% of men
whose female partner was positive for early signs of cervical
cancer by having CIN had the male equivalent, PIN [94].
This underscores the sexual transmission of high-risk HPV
associated with cancer. Oncogenic HPV was present in 75%
of patients with PIN grade I, 93% with PIN grade II, and
100% with PIN grade III, the step short of penile cancer
[94]. Moreover, the rate of PIN was 10% in uncircumcised
mencompared with6% incircumcised men[94].HPVDNA
was found in 80% of tumor specimens, with 69% of these
being the high-risk type 16 [36]. Condom use may lower
HPV infection as was reported in a study of 393 men in
Tucson, Arizona [44].Inanotherstudyof463meninTucson
and Tampa, condom use halved the prevalence of oncogenic
HPV [95]. It is therefore important to note that condom use
reduces HPV infection only partially. In the multinational
study, although high-risk HPV was lower in condom users,
this did not reach statistical signiﬁcance [45].
4.Phimosis
Phimosis is strongly associated with invasive penile carci-
noma, the adjusted OR for this being 16 in one study [16]
and 11 in another [36]. In fact 45–85% of men with penile
cancer have a history of phimosis [16, 33, 96]. Phimosis
causes dysplastic (pre-cancerous) changes in the skin of the
preputial sac [97]. Although length of the foreskin has been
suggested as a factor, the evidence for this is weak [98]. In
this study, 52% of penile cancer cases with a long foreskin
had phimosis. These ﬁndings have led to the conclusion that
circumcision in early childhood, by eliminating phimosis,
may help prevent penile cancer [36]. A meta-analysis yielded
an overall OR of 12.1 (95% CI = 5.6–26.2) (Table 2)f o rt h e
association of phimosis with penile cancer.
5.Smegma
Smegma is a whitish ﬁlm found under the foreskin of uncir-
cumcised males. It contains bacteria, other microorganisms,
dead skin cells, mucous, and other components. Evidence
for a role of smegma in the etiology of penile cancer was
obtained in an early study [102]. The carcinogenicity of
smegma was subsequently conﬁrmed by others [103–105].
It was not clear in these studies from the 1950s and 1960s
what component was responsible, but in hindsight it could
h a v eb e e nt h ep r e s e n c eo fH P V .S m e g m am a yc a u s ec h r o n i c
inﬂammation and recurrent infections that lead to preputial
adhesions and phimosis [16, 97]. Male horses produce large
amounts of smegma and 23% of cancers in these animals
are of the penis. Geldings do not get erections that would
normally help eliminate smegma, and in such horses penile
cancer is 10 times higher than in stallions [106]. In a meta-
analysis of the available data we found an OR of 3.04 (95%
CI=1.29–7.16)fortheassociationbetweenpenilecancerand
smegma (Table 3).
6.Balanitisand LichenSclerosis
These conditions are all more prevalent in uncircumcised
men. Chronic relapsing balanitis of bacterial, mycotic, or
viral origin increases the risk of invasive penile cancer [107,
108]. A history of balanitis has been reported in 45% of
penile cancer patients compared with 8% of controls [20,
96]. Penile lichen sclerosis (also termed balanitis xerotica
obliterans(BXO)),aninﬂammatory disorderthatcanleadto
meatal stenosis or phimosis, is associated with penile cancer
(reviewed in [10]). BXO is well known in boys where it is
more common than is generally assumed [109]. In penile
carcinoma patients incidence of lichen sclerosis was initially
estimated as 2.6–5.8%, but subsequent research found the
rate to be very much higher. In one study it was 28%, with
77% of patients having squamous cell carcinoma and 23%
carcinoma in situ [110]. Other studies found BXO in 33%
[111], 44% [112], and 50% [113] of cases of squamous cell
carcinoma. HPV infection was 2.6 times higher amongst
patients with penile lichen sclerosis [114]. Lichen sclerosis is
not always associated with presence of HPV and it could be
that lichen sclerosis acts as a catalyst in the onset of penile
cancer [115]. Although this and other evidence supports
the view that oncogenic HPV is more prevalent in patients
with genital lichen sclerosis (17% versus 9%), other data
suggests that lichen sclerosis is a preneoplastic condition
unrelated to HPV infection (reviewed in [10]). One review
suggested that approximately half of penile squamous cell
carcinomas (which represent 95% of penile neoplasms) are
associated with lichen sclerosis and half with HPV [91]. A
meta-analysis indicates an OR of 3.82 (95% CI = 1.61–9.06)
for the association of balanitis with penile cancer (Table 4).
7.Herpes,P oorHygiene,andOtherRiskFactors
A cocarcinogenic role of recurrent HSV-2 in penile cancer
has also been suggested [116, 117].
The widely used vaginal spermicide, nonoxynol-9, which
is abrasive, greatly increases susceptibility of the genital
epithelium to HPV16 infection [118]. The vegan alternative
to gelatin, carrageenan, a polysaccharide from red seaweed
that is a constituentof some vaginal lubricants, was shown to
prevent HPV16 infection in mice, and a clinical trial found
that it oﬀered women 47% protection against infection by
high-risk HPV when used consistently [119].
In addition, other factors, such as smoking (4.5-fold
increase in risk [36]), poor hygiene (even in the absence
of phimosis), and the presence of other STIs have been
suspected as contributing to penile cancer as well [3, 120],
but it would seem that lack of circumcision is the primary
prerequisite, with such other factors adding to the risk in
uncircumcised men. Indeed, there is no scientiﬁc evidence
that improved penile hygiene is eﬀective in reducing the risk
of penile cancer in an uncircumcised man [121], although
this factor cannot be ruled out. A case-control study inAdvances in Urology 11
Table 2: Association between phimosis and penile cancer.
Study [ref.] n/N∗ OR (95% CI) Type
Brinton et al. (1991) [99] 44/111 37.2 (11.9–116) IPC
Tsen et al. (2001) [16] 50/150 1.7 (0.32–7.8)† CIS
Tsen et al. (2001) [16] 50/150 16 (4.5–57)† IPC
Daling et al. (2005) [36] 33/308 3.8 (1.4–10.1)† CIS
Daling et al. (2005) [36] 38/313 11.4 (5.0–25.9)† IPC
Velazquez et al. (2003) [98] 23/238 14.5 (5.5–38.4) Not stated
Harish & Ravi (1995) [100] 503/1006 6.97 (4.3–11.3)† Not stated
Hellberg et al. (1987) [101] 217/414 64.6 (30.9–135) Not stated
Meta-analysis (random eﬀects): OR = 12.1 (95% CI = 5.57–26.2)
∗Total cases/total participants; †Adjusted odds ratio presented in original study.
IPC, invasive penile carcinoma; CIS, carcinoma in situ.
Table 3: Association between smegma and penile cancer.
Study [ref.] n/N∗ OR (95% CI) Type
Maden et al. (1993) [3] 80/268 2.1 (1.2–3.8)† IPC+CIS
Brinton et al. (1991) [99] 30/97 11 (3.68–32.6) IPC
Daling et al. (2005) [36] 32/308 1.4 (0.3–6.9)† CIS
Daling et al. (2005) [36] 38/314 2.4 (0.7–8)† IPC
Meta-analysis (random eﬀects): OR = 3.04 (95% CI = 1.29–7.16)
∗Total cases/total participants; †Adjusted odds ratio presented in original study.
IPC, invasive penile carcinoma; CIS, carcinoma in situ.
California found no correlation between penile cancer and
frequency of bathing or method of cleaning the anogenital
area before or after sexual intercourse [16].
It therefore seems there may be two etiologic routes to
penile cancer: one via sexual transmission of oncogenicHPV
in younger men and the other, unrelated to HPV, that mostly
aﬀects older men (reviewed in [10]). In each case, lack of
circumcision is an important precondition and major risk
factor.
8.ProstateCancer
Risk of prostate cancer correlates with a history of STIs,
most consistently syphilis, gonorrhoea, Chlamydia, and
HPV [122–129]. In contrast to penile cancer, however, no
consistent association has been seen between rate of prostate
cancer and rate of cervical cancer in diﬀerent geographic
localities [130]. A study of 20,243 men in Finland found
infection with HPV18 was associated with a 2.6-fold increase
in risk of prostate cancer (P<. 005) [131]. For HPV16
the increased risk was 2.4-fold. These ﬁgures are similar
to the increased prevalence of penile HPV infection in
uncircumcised men [45]. In contrast, a Swedish study found
an association of HPV33, but not HPV16 or HPV18, with
prostate cancer [132]. A study in Crete, however, found HPV
in only5%ofsamples, noneofwhich had thecommon high-
risk types 16 and 18, making a role for HPV unlikely [133].
Consistent with this, a study in Saudi Arabia was unable to
detectHPV in any of the prostate biopsies of 56 patients with
benign prostatic hyperplasia or prostate cancer [134].
The moloney murine leukemia virus homologue known
as xenotropic murine leukemia virus (XMRV) (gene: HPC1)
was implicated in prostate cancer, initially in patients homo-
zygous for a genetic variant of HPC1 that encodes RNase L,
an important component of antiviral defence mechanisms
[135]. In a USA study of 334 consecutive prostate resection
specimens, DNA for XMRV was found in 6% and XMRV
protein expression was found in 23% [136]. This retrovirus
was found primarily in malignant epithelial cells, consistent
with a role in tumorigenesis and tumor aggressiveness.
Its presence in that study was, moreover, independent of
polymorphism in the RNase L gene. Others have found an
element in the XMRV promoter that causes a doubling of
transcription of this gene in response to androgens [137].
XMRV replicates more eﬃciently in prostate cancer cells due
in part to the transcriptional environment [138]. A research
t e a mi nB e r l i n ,h o w e v e r ,f a i l e dt oﬁ n dX M R Vb yP C Ri n5 8 9
prostate cancers [139]. It is early days, and as yet there is no
clear evidence linking XMVR to prostate cancer [140].
ThepolyomavirusBKVhasbeenfoundin19%ofcasesof
prostate cancer in Crete, leading to a suggestion that it could
play a role in some of these [133].
Trichomonas vaginalis, the most common bacterial STI,
was positively correlated with risk of prostate cancer later
in life in the US Physicians Health Study [141]. This study
measured antibodies to T. vaginalis in samples collected a
decade before prostate cancer was diagnosed. Seropositivity
was associated with a 2-fold increased risk for advanced
prostate cancer and a 3-fold higher risk for prostate cancer
leading to death. Most men who have T. vaginalis infection
do not have symptoms. An RCT has found that circumcision12 Advances in Urology
Table 4: Association between balanitis and penile cancer.
Study [ref.] n/N∗ OR (95% CI) Type
Maden et al. (1993) [3] 100/199 1.3 (0.5–3.6)† IPC+CIS
Daling et al. (2005) [36] 74/743 3.5 (1.2–10.3)† CIS
Daling et al. (2005) [36] 62/731 3.9 (1.3–11.7)† IPC
Hellberg et al. (1987) [101] 207/400 9.49 (5.24–17.2) Not stated
Meta-analysis (random eﬀects): OR = 3.82 (95% CI = 1.61–9.06)
∗Total cases/total participants, †Adjusted odds ratio presented in original study.
IPC, invasive penile carcinoma; CIS, carcinoma in situ.
canprotectagainst T. vaginalis infection, this organism being
46% lower in the men who had been circumcised [142]. An
as-treated analysis found T. vaginalis to be even lower, 51%,
the adjusted OR being 0.41 (P = .030).
Such infections may establish a state chronic active
inﬂammation in the prostate, which is associated with a
variety of cancers [122] .T h er a t eo fS T I sh a sr i s e no v e r
the past decade in many developed countries (e.g., in the
UK there are approximately 700,000 cases per year, one-
third being in London [143]), suggesting that an increased
incidence of prostate cancer may follow.
Uncircumcised men have a 1.6- to 2.0-fold higher
incidence of prostate cancer compared with circumcised
men [144–146], and prostate cancer is rare amongst Jews
[147]. In Southern California the reduction in risk in
circumcised men was 0.5 in whites and 0.6 in blacks [128].
Similarly, in Sweden, uncircumcised males had twice the risk
[144]. Of men operated on for prostatic obstruction, only
1.8% of obstructions were cancerous in Jews (circumcised),
compared with 19% in non-Jews [146]. A study in the UK in
1996foundanORforthe reductioninrisk ofprostatecancer
in circumcised men of 0.62 [145]. Circumcision prevalence
shows an inverse correlation with prostate cancer incidence
in 51 countries (P = .022), supporting the possibility of
circumcision having a protective eﬀect against this cancer (J.
H. Waskett, unpublished).
Ascending passage of a particular STI to the prostate
could be a causative factor in prostate cancer. An extended
clinical trial of the role played by circumcision in the
prevention of prostate cancer is needed [148], but this is
likely to be a long study.
In the USA, 1 in 6 men develop/get prostate cancer dur-
ing their lifetime [1]. Annual cases in 2006 were 0.25million
[149] with an average age of diagnosis of 70 years [150]. The
circumcision prevalence among these men (born from 1933
to 1947) is approximately 60% [149]. Across the range of
a 1.6–2.0-fold increase in risk, calculations show that there
are 24–40%(45,000–67,000)more prostatecancercasesthan
would otherwise be the case if all men were circumcised
[151].
Treatment by radical prostatectomy leads to shortening
in length of the penis by an average of 1.3 cm for the ﬂaccid
penis and 2.3cm (oneinch) for the stretched penis, although
this generally resolves about a year after surgery [152].
A simple cost-beneﬁt analysis for the USA [151]c o n -
sidered an average cost for radiation therapy of US$13,823
[153] and a combined cost for terminal care of $24,660
per patient for the 41,000 who die of prostate cancer each
year [154]. Based on these ﬁgures and those above, lack of
circumcision was estimated to add $0.8–1.6 billion to the
costs of treatment and terminal care each year in the USA
[151]. This can be compared with the total for physician and
hospital costs for neonatal circumcision in the USA of $195
per infant or a total of $390 million per year [154]. Such a
comparison did not take into account indirect costs or the
contribution of prostate cancer to disability years of life lost
(DALYs).
9.The Riskto WomenfromSexual
Transmissionof High-RiskHPV
Any discussion of penile cancer in men cannot fail to
m e n t i o nc e r v i c a lc a n c e ri nw o m e n .S e x u a lt r a n s m i s s i o n
of high-risk HPV infection is responsible for virtually all
cervical cancer. The incidence of cervical cancer is 10 times
higher than that of penile cancer, with 12,000 new cases and
4,000deathsfrom cervicalcancereach year intheUSA[155].
Australian data indicate 725 cases in 2003 (incidence 9.1 per
100,000) and 212 deaths [156]. In the USA, high-risk HPVs
account for the loss of 3.3million DALYs through cervical
cancer [157]. The cost of treating cervical disease in the USA
eachyearisapproximately$3.5billion[158].Thisﬁguredoes
not portray the social cost of cervical cancer to individuals
and families.
The study in Denmark referred to earlier that found 5-
fold lower HPV in circumcised men concluded that “the
female partners of circumcised men are less exposed to
cervicalcancerbecausethesemenarelesslikelytobeinfected
with HPV” [54].
High-risk HPV types 16, 18 and over a dozen other less
common types are responsible for virtually every case of
cervical cancer [159–161] and are the same high-risk HPVs
that cause PIN, which is the precursor to penile cancerand is
the male equivalentofCIN,more oftenreferred to these days
as “squamous intra-epithelial lesion” (SIL), the precursor
to cervical cancer. Women with cervical cancer are more
likely to have partners with PIN [162]. In women with CIN,
PIN was present in the male partner in 93% of cases [94].
This is consistent with the known sexual transmission of
oncogenic HPV. CIN/SIL may progress to cancer or, more
often, it will resolve. Thus cofactors are suspected. Smegma,
obtained from under the foreskin of human and horse, was
shown to be capable of producing cervical cancer in miceAdvances in Urology 13
in one study [163], but not in another [105]. Diﬀerences in
exposure time in each study could have contributed to this
diﬀerence,and followup isneeded to conﬁrm whether or not
these old studies have any validity.
The large, well-designed, multinational study by the
International Agency for Research on Cancer published in
the New England Journal of Medicine mentioned earlier
irrefutably implicated lack of male circumcision in cervical
cancer [45]. It involved 1,913 couples in 5 global locations
in Europe, Asia, and South America. As stated earlier, penile
HPVwasfound in19.6%ofuncircumcised, butonly5.5%of
circumcised men (adjusted OR = 0.37; 95% CI = 0.16–0.85;
P<. 001). Monogamous women whose male partner had
had 6 or more sexual partners were over 5.6 times more likely
to have cervical cancer if their partner was uncircumcised
(OR = 0.18; 95% CI = 0.04–0.89). Male circumcision was
also protective in women whose partner had an intermediate
sexual behavior risk index (OR = 0.50; 95% CI = 0.27–0.94).
In this study, penile HPV infection was associated with a 4-
fold increase in the risk of cervical HPV infection in the
female partner, and cervical HPV infection was associated
with a 77-fold increase in the risk of cervical cancer. In
an accompanying editorial it was suggested that “reduction
in risk among female partners of circumcised as compared
with uncircumcised men may well be more substantial than
reported” [164].
Genital HPV types are highly infectious and can infect
skin throughout the genital region. Skin-to-skin contact that
does not extend to actual sexual penetration by an uncir-
cumcised penis could infect women. In the NEJM study
condom use provided only a slight protective eﬀect—the
odds ratio between condom users and nonusers (0.83) was
not statistically signiﬁcant [45]. A study in Seattle of uni-
versity undergraduates, however, found that HPV incidence
in women whose partners always used condoms was 70%
less than those whose partners used condoms less than 5%
of the time [165]. Squamous intraepithelial lesions were
absent in the group with 100% condom use, compared
with an incidence of 15 per 100 patient-years in non-users.
Interestingly, the uncircumcised men washed their genitals
more often after intercourse, but the circumcised men had
better penile hygiene when examined by a physician. So why
are uncircumcised men more likely to get infected? One
suggested reason is that the more delicate, mucosal lining
of the foreskin is pulled back fully or partially during inter-
c o u r s e ,e x p o s i n gi tt ot h ev a g i n a ls e c r e t i o n so fa ni n f e c t e d
woman. The higher incidenceof HPV in uncircumcised men
translates into an increased risk of infection to future sexual
partners.
An ecological analysis of data from 117 developingcoun-
tries revealed a cervical cancer incidence of 35 per 100,000
women per year in 51 countries with a low (<20%)
circumcision prevalence compared with 20 per 100,000 in
52 countries with a high (>80%) circumcision prevalence
(P<. 001) [166]. Of all factors examined, male circumcision
had the strongest association with cervical cancer incidence.
A meta-analysis of 14 studies up until September2007 (5
intheUSA,2inMexico,2inAustralia,andoneeachinSouth
Korea, Denmark, England, Kenya, and the multinational
study involving Brazil, Spain, Thailand, and The Philippines
referred to above) found an OR of 0.75 (95% CI 0.49–1.14)
for the association between male circumcision and cervical
cancer in monogamous women [67].
A RCT in Rakai, Uganda, studied the female partners of
men who underwent circumcision and those of men who
remained uncircumcised [167]. Of these women, 84% were
monogamous and 97% had had only one sex partner in
the previous year. At the 2-year point an as-treated analysis
showed that the 544 whose male partner had been circum-
cised had a lower prevalence of high-risk HPV infection
(28%) than the 488 whose male partner was uncircumcised
(38%): PRR = 0.75. For low-risk HPV these ﬁgures were
35% and 41%, respectively (PRR = 0.83). The prevalence of
multiple high-risk HPV was 8.9% and 12.6%, respectively,
g i v i n ga nI R Ro f0 . 7 1 ,w h i l et h a to fm u l t i p l el o w - r i s kH P V
was 9.2% and 14.2% (IRR = 0.65). Between enrolment
and year 2 the prevalence of high-risk HPV decreased by
7.4% (P = .006)inthe women whose male partner had been
circumcised, but did not change signiﬁcantly (+1.6%) in the
women whose male partner had remained uncircumcised.
Thestudyalsofoundthatby2yearswomenwithcircumcised
partners had cleared 82% of high-risk HPV acquired during
the ﬁrst year of the trial, compared with 70% for women
with uncircumcised partners (P = .14). The authors pointed
out that the estimated eﬃcacy of male circumcision in
prevention of high-risk HPV (28%) could, for a number of
reasons, have been an underestimate.
Thus the epidemic of cervical cancer worldwide in
women would appear to be facilitated, at least in part,
by the lack of circumcision in men. We speculate that in
countries that have experienced a downturn in the uptake
of neonatal circumcision, as occurred in the USA and to
a greater extent in Australia in the late 1970s and 1980s,
the incidence of cervical cancer can be expected to increase.
This is because these males would now have reached sexual
maturity. The higher proportion of uncircumcised men in
the male population increases the overall risk to women
today, more than would otherwise have been the case if male
circumcision prevalence had remained high.
Prophylactic vaccines against HPV 16 and 18 became
available for administration to girls prior to sexual activity
in 2007. These two HPVs represent 70% of the HPV types
found in cervical cancers. They were also the two genotypes
that had the highest population prevalence in the past. In
2007, however, the CDC reported that HPV 16 and 18 are
now less prevalent, type 16 becoming only the 6th most
common and HPV18 now being even less prevalent [168].
Moreover, replacement of types 16 and 18 by other HPV
types not included in current vaccines could occur. Other
concerns include the very high ongoing costs of vaccination
programs, levels of uptake, the possibility of the need for
booster doses if eﬃcacy wanes over time, weak cross-
genotype immunity, poor eﬃcacy in women with prior HPV
16 and 18 infections, and the false belief that the vaccines
protect against all cervical cancer, which may result in fewer
women continuing to participate in screening programs or
practicing safe sex.14 Advances in Urology
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Figure 4: Fixed eﬀects forest plot models of the unadjusted risk ratios for (a) any high-risk HPV and for (b) multiple high-risk HPV
infections detected at the coronal sulcus/glansin circumcised and uncircumcised men. The data are derived from both observational studies
and randomized trials, and include HPV prevalence and incidence estimates. The unadjusted risk ratios diﬀer from the adjusted odds
ratios reported in some studies, because the odds ratio does not approximate to the risk ratio with common disease outcomes such as
HPV, and because adjustment for risk behaviors may aﬀect estimates. Nevertheless, the ﬁndings are in general consistent across studies as
indicated by the nonsigniﬁcant tests for heterogeneity and suggest that, in aggregate, circumcision may reduce any high-risk HPV infection
by approximately 36%, and multiple high risk HPV infections by 57%.
Various studies have demonstrated increasing infection
with genital HPV types at a younger age. In the UK, 5% of
girls under 14 had HPV antibodies, indicating current or
prior infection [169]. By age 16 this was 12%, by 18 it was
20%, and by age 24 the proportion infected was 45%, with
a subsequent decrease thereafter. Oncogenic HPV16 was the
most common type. In the USA, 7% of teenagers (ages 12–
19)had HPV16 antibodies, rising to25%for20–29-yearolds
[170]. Chlamydia and genital herpes cases are also rising in
teenagers in developed countries.
HPVcanbetransmittedtothemouthduringoralsexand
is an independentrisk factor for someoropharyngeal cancers
[171].
It should be noted that there might be as many as 200
types of HPV, up to 50 of which have been described in the
anogenital region. Most of these range from uncommon to
extremely rare. The numberofHPVtypesrelevant to screen-
ingforcervicalcancerriskinthepopulationisapproximately
20. Ideally, many expect that vaccination against the most
common types (HPV 16 and 18) could preventtwo-thirds of
cervical cancers. A randomized, placebo-controlled, double-
blind trial involving 5,455 women aged 16–24 years found
that vaccination reduced the rate of cervical lesions by only
20% [172]. The study lasted only 3 years however. One study
found HPV vaccination to not be cost-eﬀective, even under
favourable assumptions for vaccination programs [173]. Yet
as u b s e q u e n tr e v i e wo fc o s t - e ﬀectiveness studies concluded
that vaccination of girls against HPV will be cost-eﬀective
[174].Atanuptakeof80%in12year-old girls, HPVvaccines
could reduce cervical cancer by 38–82% over 60 years of an
ongoing vaccination programme, should vaccine protection
last 20 years [175]. Vaccination of boys has, however, been
found to not be cost-eﬀective [174, 175].
Complete elimination of HPV 16 and 18 from the
population by vaccination might, under optimal conditions
of uptake and eﬃcacy, take 20–30 years or more. In the
meantime at the population level, other oncogenic HPV
types not included in vaccines might take over and replace
these two types of HPV [176]. Participation in vaccina-
tion programs has been impeded by the “religious right”
who have expressed concerns that vaccination will increase
promiscuity. Moreover, like the anticircumcision movement,
vigorous anti-immunization lobby groups also exist. Most of
the adverse events that have received publicity in the newsAdvances in Urology 15
media were not related to the vaccine in the ﬁrst place and
would be seen in any large-scale vaccination program by
pure coincidence. One exception might be Guillain-Barre
syndrome, which is known to be an uncommon adverse
consequence of vaccination in a minority of individuals. The
two HPV vaccines currently on the market appear to be at
least as safe as any other vaccine, although HPV vaccines can
increase tumour invasiveness if a tumour is present [177].
Given the high cost of vaccinating all girls compared
with the lesser cost and proven protective eﬀect of universal
male circumcision against a raft of other conditions and
diseases in men [178, 179], the latter would appear to be a
betterinvestment.Inwomenitwouldhelpreducetheburden
of cervical cancer, and, more recently, the possiblity of a
smallproportionofbreastcancers[180–186],butalsoherpes
simplex virus type 2 [55, 187, 188], less assuredly Chlamydia
trachomatis [189, 190], then Trichomonas vaginalis, bacterial
vaginosis, genital ulceration [179, 191–193], and bacterial
vaginosis associated with CIN/SIL [194].
10.Conclusion
There is now overwhelming evidence that male circumcision
aﬀords very strong protection against penile cancer. Unlike
the many other conditions that aﬀe c tu pt oh a l fo fu n c i r -
cumcisedmalesovertheirlifetime[178],penilecanceraﬀects
only about 0.1% of uncircumcised men. Although rare,
its devastating eﬀect and poor prognosis in those aﬀected,
and impact on their families, should not be downplayed,
especially in the developing countries where penile cancer
rates are highest and treatment options are limited. Very
importantly, given its role in protecting against cervical
cancer, HIV, other STIs and medical conditions, programs
aimed at increasing infant male circumcision now would
be an excellent investment of public monies for the long
run. They would complement the enormously expensive
vaccination programs targeting two of the over 15 high-risk
HPV types that cause cervical cancer. This strategy would
add the many other beneﬁts of male circumcision to the
equation [178, 179].
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